INCANNEX HEALTHCARE INC

IXHLNASDAQ

🏆 #4170 by market capEarnings Oct 5US Equity

$3.17▼ $0.03 (−1.09%)

Live

1h▼ 1.7%

24h▼ 1.1%

7d▲ 2.8%

14d▲ 11.1%

30d▼ 3.8%

1y▼ 75.0%

🏦Market Cap

$38M

Small Cap

📈Revenue Growth (YoY)

+616.7%

High Growth

📊Gross Margin

-192.7%

Thin

💵FCF Margin

-15370.2%

Thin

⚖️P/S Ratio

568.4x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $3.14 – $3.19
52-Week Range: $2.49 – $27.69
Volume: $1.91B
Avg Volume: $1.55B
Shares Outstanding: 12.0M
Next Earnings: Sep 9, 2026

Fundamentals Snapshot

Annual Revenue: $86,000
Last Q Revenue: $23,947
P/E Ratio: -1.4
P/S Ratio: 568.4x
EPS (TTM): $-4.04
Dividend Yield: 0.00%

Why Investors Own IXHL

✓High-growth profile — revenue up +11.0% YoY with expanding US Equity exposure.
✓Healthy economics — 38% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$86,000▲ +8.6% YoY

Gross Margin (TTM)

38.4%▲ +1.8% YoY

Operating Income (TTM)

$23,650▲ +8.6% YoY

Free Cash Flow (TTM)

$17,200▲ +8.6% YoY

About INCANNEX HEALTHCARE INC

Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.

🦦